Navigation Links
Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
Date:8/24/2010

NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the company's commercialization efforts of PermaDerm™, Regenicin's proprietary autologous cultured skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

In addition to his efforts in founding Amgen, Dr. Rubinfeld has a forty-year history in pharmaceutical and consumer product development.  His accomplishments include the creation of the multi-billion dollar antibiotic Amoxicillin as well as the first synthetic biodegradable detergent. He has obtained over 100 patents during his distinguished career.  

Commenting on his decision to join Regenicin, Dr. Rubinfeld stated, "With the recent acquisition of the rights to this revolutionary technology, Regenicin is in a position to be the only company in the world capable of quickly growing and grafting a person's own skin. This is a critical development for the multi-billion dollar treatment market for burns and other wounds that are currently dependent on cadaver and pig skin," said Dr. Rubinfeld.  "These methods often have high rejection rates compared to virtually no rejection issues when a person's own skin is being used for grafting. I look forward to helping the team at Regenicin navigate through the final hurdles toward commercialization of this life improving technology."  

Dr. Rubinfeld began his career as a research scientist with several pharmaceutical and consumer product companies including Schering Plough and Colgate Palmolive. He served for 12 years at Bristol Myers, where in addition to developing Amoxicillin and Chephadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. After co-founding Amgen in 1980 and serving as its chief of operations, Dr. Rubinfeld has served as an advisor or Board member to a number of companies including AVI BioPharma and Quark Pharmaceuticals. In 1991 he co-founded Supergen, a drug development company based in Dublin, California, where he served as President and CEO until 2003 and as a member of the Board of Directors until 2005.  During that time he oversaw the company's initial public offering and its rise to a multi-billion dollar market capitalization. Management believes his wealth of experience in biotech and big pharma will be instrumental for Regenicin as it transitions to commercialization.

"We are honored to have Dr. Rubinfeld join our board," said Randall McCoy, Chief Executive Officer, Regenicin. "His expertise in regulatory product approval processes and subsequent commercialization will prove invaluable to Regenicin as we enter this new phase in our company's history and bring PermaDerm™ to patients worldwide."

About Regenicin, Inc.

Regenicin, Inc. is a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in New York, NY. Additional information can be found on the company's website, http://www.regenicin.com and in the company's filings with the Securities and Exchange Commission located at www.sec.gov.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer
2. Protectus Medical Devices Appoints as Medical Director a Physician Surgeon With 20-Year Involvement in Senior Level Monitoring of Pharmaceutical and Medical Devices
3. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
4. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
5. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
6. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
7. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
8. Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors
9. Elsevier Appoints Martin OMalley as Managing Director of New Global Sales Group in Science & Technology Division
10. Avrio Appoints David L. Gelber to Director of Manufacturing
11. Accuray Appoints Peter Fine to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will ... Members of its senior management team will host a conference call ... ET. The dial-in number to access the call ... and the passcode is 45397076. Please dial in 10 minutes prior ... A replay of the call will be available from August ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, is bringing Isle ... the remainder of the 2017 season. One of our best development riders, Brand is ... , “Every season we are excited to move an athlete from our pipeline up ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Capillus, LLC ... treat hereditary hair loss. The new Flexible Fitting Design offers a more comfortable, adaptable ... LLC is delighted with the improvements to the home-use laser therapy caps intended to ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs face is ... samples and a lengthy freeze dry cycle are a few common challenges that can ... as well as new accessories and advancements in laboratory freeze dryers that will improve ...
(Date:7/26/2017)... ... 2017 , ... It's time to sign up for the new One-A-Month Essential Oil ... Heshelow, founder of Sublime Naturals and author of numerous books on essential oils. , ... by the 5th. , Two items are included in the December mailing. ...
(Date:7/26/2017)... Jupiter, Florida (PRWEB) , ... July 26, 2017 ... ... care for dogs and cats has opened in Jupiter. The state of ... patients (cardiology) and class leading treatments with a goal of providing heart patients ...
Breaking Medicine News(10 mins):